The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients (pts) with stage III colon cancer (CC): Final results of Japan Clinical Oncology Group study (JCOG0205).
Yasuhiro Shimada
No relevant relationships to disclose
Tetsuya Hamaguchi
No relevant relationships to disclose
Yoshihiro Moriya
No relevant relationships to disclose
Norio Saito
No relevant relationships to disclose
Yukihide Kanemitsu
No relevant relationships to disclose
Nobuhiro Takiguchi
No relevant relationships to disclose
Masayuki Ohue
No relevant relationships to disclose
Takeshi Kato
No relevant relationships to disclose
Yasumasa Takii
No relevant relationships to disclose
Toshihiko Sato
No relevant relationships to disclose
Naohiro Tomita
No relevant relationships to disclose
Shigeki Yamaguchi
No relevant relationships to disclose
Makoto Akaike
No relevant relationships to disclose
Hideyuki Mishima
No relevant relationships to disclose
Yoshiro Kubo
No relevant relationships to disclose
Junki Mizusawa
No relevant relationships to disclose
Kenichi Nakamura
No relevant relationships to disclose
Haruhiko Fukuda
No relevant relationships to disclose